Cargando…

Antitumor effect of TW-37, a BH3 mimetic in human oral cancer

TW-37 is a small molecule B cell lymphoma-2 (Bcl-2) homology 3 mimetic with potential anticancer activities. However, the in vivo anti-cancer effect of TW-37 in human oral cancer has not been properly studied yet. Here, we attempted to confirm antitumor activity of TW37 in human oral cancer. TW-37 s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Chi-Hyun, Lee, Won Woo, Jung, Yun Chan, Shin, Ji-Ae, Hong, Kyoung-Ok, Choi, Sujung, Swarup, Neeti, Kim, Jihoon, Ahn, Min-Hye, Jung, Minjung, Cho, Sung-Dae, Jin, Bohwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081630/
https://www.ncbi.nlm.nih.gov/pubmed/32257914
http://dx.doi.org/10.1186/s42826-019-0028-7
Descripción
Sumario:TW-37 is a small molecule B cell lymphoma-2 (Bcl-2) homology 3 mimetic with potential anticancer activities. However, the in vivo anti-cancer effect of TW-37 in human oral cancer has not been properly studied yet. Here, we attempted to confirm antitumor activity of TW37 in human oral cancer. TW-37 significantly inhibited cell proliferation and increased the number of dead cells in MC-3 and HSC-3 human oral cancer cell lines. TW-37 enhanced apoptosis of both cell lines evidenced by annexin V/propidium iodide double staining, sub-G(1) population analysis and the detection of cleaved poly (ADP-ribose) polymerase and caspase-3. In addition, TW-37 markedly downregulated the expression of Bcl-2 protein, while not affecting Bcl-xL or myeloid cell leukemia-1. In vivo, TW-37 inhibited tumor growth in a nude mice xenograft model without any significant liver and kidney toxicities. Collectively, these data reveal that TW-37 may be a promising small molecule to inhibit human oral cancer.